Global HIV TB CAPRISA operates as a UNAIDS collaborating centre focused on HIV prevention, pathogenesis, and the HIV-TB interface, presenting opportunities for partnerships in infectious disease research, clinical studies, and trial collaborations with funders and industry players.

Phase II bnAb Trial Recent presentation at the International AIDS Conference demonstrates CAPRISA's capability to run advanced clinical studies, specifically long-acting broadly neutralising antibodies for HIV prevention, indicating potential for contract research, protocol development, and investigator-initiated trials.

Strategic Collaborations CAPRISA’s origin through multiple universities and national institutes highlights a strong network and credibility for joint research proposals, technology transfer discussions, and co-development opportunities with global biopharma and academia.

Funding Footing With estimated revenue in the mid-range of tens of millions, CAPRISA operates at a scale suitable for grant-driven projects, sponsored studies, and capacity-building programs, suggesting opportunities for multi-year contracts and consortium funding.

Digital Engagement Active dissemination through social channels and a web presence indicates readiness for outreach, sponsorships, and participation in industry conferences, enabling lead generation, thought leadership collaborations, and discovery by potential partners.